News Archives - Page 3 of 4 - NFCR

News

FDA Approves First Cancer Drug Based on Genetics… Not Tumor Location

Just last week, the U.S. Food and Drug Administration approved the cancer medicine— Keytruda® (generic name pembrolizumab)— to treat cancers that have a specific genetic mutation or biomarker. This is the first time a cancer treatment has been approved based on a biomarker rather than the body location where the…...

Read more

Attacking Metastatic Tumors in the Brain

Targeting HER3 could cripple metastatic cancers that have spread to the brain. (Bethesda, MD, June 5, 2017) Rakesh Jain, PhD, Director of the Edwin L. Steele Laboratory for Tumor Biology at the Massachusetts General Hospital and supported by the National Foundation for Cancer Research, has discovered a novel mechanism behind…...

Read more

Highlights of ASCO 2017

Founded in 1964, the American Society of Clinical Oncology (ASCO®) is the world’s leading professional organization for physicians and oncology professionals caring for people with cancer. Each year, tens of thousands of oncology professionals, cancer researchers and patient advocates gather at The ASCO Annual Meeting  to discuss the latest in…...

Read more

NFCR President Wins International Cooperation Award from the Chinese Medical Doctor Association

NFCR President receives the inaugural award from Society for Neuro-Oncology of the Chinese Medical Doctor Association for her outstanding contribution to international cooperation in March 2017.   Dr. Jiang Tao, the Chairman of the Society for Neuro-Oncology of the Chinese Medical Doctor Association and the vice director of the department…...

Read more

New Treatment for Glioblastoma Multiforme Developed by NFCR Scientists

Dr. Web Cavenee and Dr. Paul B. Fisher discover a new pharmacological agent to treat glioblastoma multiforme (GBM), the deadliest brain cancer....

Read more

NFCR’s Dr. Web Cavenee Honored at Prestigious Gray Gala

NBTS held its annual Gray Gala and pioneers in brain tumor research were honored, including Dr. Web Cavanee, Chairman of NFCR’s Scientific Advisory Board....

Read more

NFCR-Funded Scientist Selected as ‘Giant of Cancer Care’

Dr. Daniel Von Hoff, Director of the NFCR Center for Targeted Cancer Therapies at TGen, has been selected as a 2016 Giants of Cancer Care® by OncLive....

Read more

Research by NFCR Scientists Reveals New Insights into Treatment Resistance of Metastatic Breast Cancer

Oscillating expression of a key cancer gene may impact treatment approaches for patients NFCR-supported scientist Dr. Daniel Haber and his team at the Massachusetts General Hospital Cancer Center have identified a dynamic gene expression in metastatic breast cancer that may contribute to disease progression and resistance to treatment experienced by many…...

Read more

Welcoming Alaska Airlines Mileage Plan

We are pleased to welcome Alaska Airlines Mileage Plan as the newest way to earn with Fly to Find a Cure.  Along with its Global Partners, Alaska Mileage Plan offers its members the ability to earn and redeem miles to over 800 destinations around the world.  With this new earning opportunity, you…...

Read more